financetom
Business
financetom
/
Business
/
Future Vision II Acquisition Closes IPO
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Future Vision II Acquisition Closes IPO
Sep 13, 2024 12:24 PM

01:59 PM EDT, 09/13/2024 (MT Newswires) -- Future Vision II Acquisition ( FVNNU ) closed its initial public offering of 5.75 million units, including 750,000 units for the underwriter's full exercise of an overallotment option.

Priced at $10 per unit, the offering resulted in gross proceeds of $57.5 million, the blank-check company said.

The units started trading Thursday on the Nasdaq under the ticker FVNNU.

Each unit comprises one ordinary share and a right to receive a 10th of a share upon completion of an initial business combination, Future Vision said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Winnebago's Fiscal Q2 Adjusted Earnings, Revenue Drop -- Shares Fall Pre-Bell
Winnebago's Fiscal Q2 Adjusted Earnings, Revenue Drop -- Shares Fall Pre-Bell
Mar 21, 2024
08:00 AM EDT, 03/21/2024 (MT Newswires) -- Winnebago Industries ( WGO ) reported fiscal Q2 adjusted earnings Thursday of $0.93 per share, down from $1.88 a year earlier. Analysts polled by Capital IQ expected $0.86. Revenue for the quarter ended Feb. 24 was $703.6 million, down from $866.7 million a year earlier. Analysts surveyed by Capital IQ expected $710.9 million....
Theratechnologies Initiates Higher Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Theratechnologies Initiates Higher Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Mar 21, 2024
08:00 AM EDT, 03/21/2024 (MT Newswires) -- Theratechnologies Inc. ( THTX ) on Thursday said it is moving to the next dose level in Part 3 of its Phase 1 clinical trial of sudocetaxel zendusortide in patients with advanced ovarian cancer. The study's Medical Review Committee (MRC) has deemed the dose level in the first cohort of patients safe and...
Darden Restaurants cuts annual sales forecast on slowing demand
Darden Restaurants cuts annual sales forecast on slowing demand
Mar 21, 2024
March 21 (Reuters) - Olive Garden ( DRI ) parent Darden Restaurants ( DRI ) lowered its annual same-store sales forecast on Thursday, as customers avoid dining out to keep their spending under check amid inflation. Shares of the Orlando, Florida-based company, which has casual and fine dining restaurant brands, fell nearly 4% in premarket trading after Darden also missed...
European airline CEOs say industry consolidation vital
European airline CEOs say industry consolidation vital
Mar 21, 2024
BRUSSELS, March 20 (Reuters) - Airline executives called for further industry consolidation on Wednesday as the EU weighs a deal between Germany's Lufthansa and Italy's ITA Airways and hits pause on a separate transaction between IAG and Air Europa. Europe's airline industry has been gradually consolidating for the last 20 years but remains fragmented, with small national carriers struggling to...